Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 6/20 | 0.56 |
| ▸ | CDC25A | P30304 | 1/20 | 0.55 |
| ▸ | CDC25C | P30307 | 1/20 | 0.55 |
| ▸ | DHODH | Q02127 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28322767 | 0.88 | TSHR (0.56) | CDC25BKDM4ELMNAMAPTCYP1A2 | |
| SCHEMBL21765032 | 0.86 | MAPT (0.69) | KDM4ELMNAMAPTCYP1A2CYP2C9 | |
| SCHEMBL10597386 | 0.86 | LMNA (0.71) | CDC25BCDC25ACDC25CLMNACYP1A2 | |
| SCHEMBL3630708 | 0.85 | KDM4E (0.67) | CDC25BCDC25ACDC25CKDM4ELMNA | |
| SCHEMBL2008034 | 0.84 | MAPT (0.71) | CDC25BCDC25ACDC25CKDM4ELMNA | |
| SCHEMBL10833818 | 0.83 | CDC25B (0.65) | CDC25BCDC25ACDC25CKDM4ELMNA | |
| SCHEMBL10631533 | 0.82 | LMNA (0.78) | LMNAMAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL22556332 | 0.81 | NPSR1 (0.47) | DHODHKDM4ELMNAMAPTNPSR1 | |
| SCHEMBL10834780 | 0.81 | ALDH1A1 (0.65) | CDC25BCDC25ACDC25CDHODHKDM4E | |
| SCHEMBL25279533 | 0.80 | AKR1C3 (0.60) | MAPTHTTTAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| EP-3793551-A1 | OXADIAZOLE COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| WO-2019222431-A9 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| WO-2019222431-A9 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | YAP1, TEAD2, TEAD3 | CDC25B 1110/4885CDC25A 1137/4885CDC25C 526/4885 |
| US-11661403-B2 | Oxadiazole compounds | YAP1, TEAD2, TEAD3 | CDC25B 1110/4885CDC25A 1137/4885CDC25C 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.